Trials / Completed
CompletedNCT04646889
Pharmacokinetic Study of AR882 in Subjects With Various Degrees of Renal Impairment
A Phase 1, Pharmacokinetic and Pharmacodynamic Study of AR882 in Adult Volunteers With Various Degrees of Renal Impairment
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 46 (actual)
- Sponsor
- Arthrosi Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
This is a 2-segment, multi-center, phase 1, open-label, study evaluating the pharmacokinetics and pharmacodynamics of AR882 in subjects with various degrees of renal impairment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AR882 Single Dose | A single dose of AR882 |
| DRUG | AR882 Multiple Dose | AR882 taken once daily for 14 days |
Timeline
- Start date
- 2021-01-14
- Primary completion
- 2022-06-27
- Completion
- 2022-06-27
- First posted
- 2020-11-30
- Last updated
- 2022-08-05
Locations
4 sites across 2 countries: United States, New Zealand
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04646889. Inclusion in this directory is not an endorsement.